INanoBio is building a 3D nanopore‑transistor sequencing platform on CMOS technology that can read whole human genomes with high accuracy at roughly one‑tenth the current cost and over 100 × faster than existing protein nanopore sequencers.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genome sequencing technologies are expensive and slow, limiting large‑scale population studies and timely precision‑medicine applications. Early cancer detection often requires invasive biopsies because blood‑based biomarkers are difficult to measure with sufficient sensitivity.
Solution
INanoBio is developing a 3D nanopore‑transistor sequencing platform built on CMOS semiconductor technology that can read whole human genomes with high accuracy at roughly one‑tenth the cost and over 100 × faster than existing protein nanopore sequencers. The rapid, low‑cost sequencing enables population‑scale genomic analysis for personalized disease risk assessment and therapy selection. In parallel, the company creates ultra‑sensitive nano‑biotech blood tests that detect cancer‑specific molecular biomarkers, allowing non‑invasive early diagnosis and reducing reliance on tissue biopsies.
Target Audience
Primary customers include research institutions, public health genomics programs, and clinical laboratories that require fast, affordable whole‑genome sequencing, as well as oncology diagnostic labs seeking highly sensitive, non‑invasive cancer screening tests.
Features
- 3D nanopore‑transistor device leveraging CMOS fabrication for scalable, high‑throughput genome sequencing
- Projected sequencing speed >100 × faster than protein nanopore platforms, reducing run time from days to hours
- Target cost per genome at ~10 % of current market pricing, facilitating large‑scale population studies
- High‑accuracy base calling enabled by integrated transistor readout and advanced signal processing
- Nano‑biotech blood assay platform with ultra‑high sensitivity for detecting low‑abundance cancer biomarkers
- Simple blood draw workflow that eliminates the need for invasive tissue biopsies